Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (4)
  • Autophagy
    (2)
  • FGFR
    (5)
  • FLT
    (6)
  • PDGFR
    (8)
  • TAM Receptor
    (3)
  • VEGFR
    (8)
  • c-Kit
    (9)
  • c-Met/HGFR
    (3)
  • Others
    (9)
Filter
Search Result
Results for "

RTK

" in TargetMol Product Catalog
  • Inhibitor Products
    28
    TargetMol | Activity
  • Recombinant Protein
    5
    TargetMol | inventory
  • Peptides Products
    1
    TargetMol | natural
  • Natural Products
    1
    TargetMol | composition
FGF/PDGF/VEGF RTK Inhibitor
T71944144335-37-5
FGF/PDGF/VEGF RTK Inhibitor is a potent, reversible, atp-competitive inhibitor against pdgfrβ, fgfr-1, and vegfr-2 (ic50 = 20, 90, and 240 nm, respectively) and effectively suppresses vegf-stimulated proliferation of hmvecs (ec50 = 420 nm).
  • $1,520
6-8 weeks
Size
QTY
Pexidartinib
T21151029044-16-3
Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
SAR125884 hydrochlorid (1116743-46-4(free base))
T5677
SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
  • $53
In Stock
Size
QTY
EGF Receptor Peptide Acetate
T21723L
Epidermal Growth Factor Receptor Peptide Acetate (Epidermal Growth Factor Receptor Peptide Acetate(96249-43-3 Free base)) exists on the cell surface and is activated by the binding of its specific ligands.EGFR belongs to the ErbB family of receptor tyrosine kinases (RTK).
  • $41
In Stock
Size
QTY
Sitravatinib
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα β, PDGFR, and Axl.
  • $47
In Stock
Size
QTY
TargetMol | Citations Cited
Afatinib Dimaleate
T1773850140-73-7
Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Sunitinib
T0374L557795-19-4
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80/2 nM). Sunitinib has antitumor activity and can be used for the treatment of kidney cancer and gastrointestinal tumors.
  • $53
In Stock
Size
QTY
TargetMol | Citations Cited
Oxindole
Fr1674159-48-3
Oxindole (Indolin-2-one) is an aromatic heterocyclic building block. 2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.Oxindole structure has been used in receptor tyrosine kinases (RTKs) inhibitors such as SU4984 and intedanib, the RTK family represents an important therapeutic target for anti-cancer drug development.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Sale
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
T36102183322-18-1
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5
  • $51
7-10 days
Size
QTY
Axl/Mer/CSF1R-IN-1
T725742394874-60-1
Axl/Mer-IN-1 is a compound that functions as an inhibitor for Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R, exhibiting dissociation constants (Kds) of less than 0.1 μM.
  • $2,120
8-10 weeks
Size
QTY
SSR128129E
T6082848318-25-2
SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting other related RTKs.
  • $34
In Stock
Size
QTY
Sitravatinib malate
T129252244864-88-6
Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
  • $1,520
1-2 weeks
Size
QTY
TNO155
T131761801765-04-7
TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 µM),with potential antineoplastic activity.
  • $91
In Stock
Size
QTY
AG 1295
T1413771897-07-9
AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4].
  • $47
In Stock
Size
QTY
Dovitinib
T6289405169-16-6
Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3 c-Kit, IC50: 1 2 nM), also effective to class IV (FGFR1 3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to EGFR, InsR, EphA2, c-Met, IGF-1R, Tie2, and HER2.
  • $39
In Stock
Size
QTY
Toceranib Phosphate
T7394874819-74-6
Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1 KDR, PDGFR
  • $41
In Stock
Size
QTY
Toceranib
T13178356068-94-5
Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
  • $39
In Stock
Size
QTY
Cabozantinib S-malate
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
  • $40
In Stock
Size
QTY
JNJ-10198409
T15616627518-40-5
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
  • $47
In Stock
Size
QTY
Trk-IN-10
T618722700265-61-6
Trk-IN-10 (Compound 14j) is a highly effective inhibitor of TRK, with an IC50 of 0.86 nM against TrkA and 6.92 nM against TrkA G595R. As an RTK, Trk plays a crucial role as a drug target in solid tumors. Trk-IN-10 (IC50 = 350 nM against ALK) demonstrates superior selectivity in inhibiting Trk, which has potential implications for toxicity reduction [1].
  • $1,520
8-10 weeks
Size
QTY
EtDO-P4
T63600245329-78-6
EtDO-P4 is a nanomolar inhibitor of sphingolipid (GSL) synthesis. etDO-P4 inhibits EGFR-induced activation of the ERK pathway and various receptor tyrosine kinases (RTK). etDO-P4 can be used to study a variety of tumor types, such as Burkitt's lymphoma.
    7-10 days
    Inquiry
    Dovitinib lactate hydrate
    T6479915769-50-5
    Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
    • $50
    In Stock
    Size
    QTY
    SHP2-IN-13
    T786942951854-02-5
    SHP2-IN-13 is an orally active, highly selective allosteric inhibitor targeting the SHP2 “tunnel site,” exhibiting an IC50 of 83.0 nM. It holds potential for research into cancers with RTK oncogenic drivers and diseases associated with SHP2.
    • $1,520
    6-8 weeks
    Size
    QTY
    Trk-IN-11
    T620932700265-62-7
    Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK, with IC50 values of 1.4 nM for TrkA and 1.8 nM for TrkA G595R. Trk-IN-11 has shown research potential in cancer diseases.
    • $1,520
    8-10 weeks
    Size
    QTY
    ON123300
    T69201357470-29-1
    ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
    • $39
    In Stock
    Size
    QTY
    IACS-13909
    T91962160546-07-4
    IACS-13909 (BBP-398), a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway.
    • $96
    In Stock
    Size
    QTY
    SAR125844
    T54671116743-46-4
    SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
    • $31
    In Stock
    Size
    QTY
    Dovitinib Dilactic Acid
    T6193852433-84-2
    Dovitinib Dilactic Acid (Dovitinib (TKI-258) Dilactic Acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3 c-Kit) with IC50 of 1 nM 2 nM, also potent to class IV (FGFR1 3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.
    • $75
    4-6 weeks
    Size
    QTY